Congenital adrenal hyperplasia therapy reshapes around CRF1 receptor antagonism
Crinecerfont approval, follow-on CRF1 receptor antagonist programs, and structured care infrastructure are reshaping classic congenital adrenal hyperplasia management.
Classic congenital adrenal hyperplasia (CAH) has been a glucocorticoid-and-mineralocorticoid replacement category for decades. The structural challenge is that high-dose glucocorticoid suppression of ACTH (needed to control androgen excess) causes substantial long-term side effects. Crinecerfont (a CRF1 receptor antagonist) carries approval for classic CAH and reduces the glucocorticoid dose needed to control androgen excess, follow-on CRF1 receptor antagonist programs are in late-stage trials, and structured CAH care infrastructure is emerging.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.